BRE binds to the cytoplasmic domains of tumor necrosis factor receptor-1 and Fas, and in cell lines can attenuate death receptor-initiated apoptosis by inhibiting t-BIDinduced activation of the mitochondrial apoptotic pathway. Overexpression of BRE by transfection can also attenuate intrinsic apoptosis and promote growth of the transfected Lewis lung carcinoma line in mice. There is, however, a complete lack of in vivo data about the protein.
Introduction
Apoptosis plays an essential role in cellular homeostasis, which impacts normal growth, defense against infection and abnormal cellular changes (Vaux and Korsmeyer, 1999; Barber, 2001) . Cells receive external signals through surface death receptors, such as the widely expressed tumor necrosis factor receptor-1 and Fas (Nagata, 1997; Aggarwal, 2003) , or internal stress signals such as DNA damage (Dive et al., 1992) , to undergo the extrinsic or intrinsic pathway of apoptosis, respectively (Strasser et al., 1995) . In a yeast two-hybrid experiment designed to isolate novel intracellular binding proteins of tumor necrosis factor receptor-1, brain and reproductive organ-expressed protein (BRE) was identified as one such protein that binds to the juxtamembrane domain of the death receptor (Gu et al., 1998) . BRE was first discovered as a ultraviolet-responsive gene, whose transcription could also be downregulated by a DNA-damaging chemical, 4-nitroquinoline-1-oxide, and a differentiation-inducing agent, retinoic acid (Li et al., 1995) . More recently, we have shown that BRE binds also to Fas. Using CD95 type II cell lines, HeLa and Jurkat, whose Fas-induced apoptotic response depends on mitochondrial amplification (Scaffidi et al., 1998; Engels et al., 2000) , we have further demonstrated that overexpression of BRE by transfection can inhibit release of the proapoptotic mitochondrial proteins, resulting in attenuation of death receptor-initiated apoptosis. Depletion of BRE by small interfering RNA (siRNA), on the other hand, can only enhance extrinsic apoptosis, but not the intrinsic apoptotic response to the genotoxic agent, etoposide. Thus, BRE is a death receptor-specific antiapoptotic protein, which acts like a functional converse of truncated BID (t-BID) by blocking the crosstalk between the extrinsic and intrinsic apoptotic pathways. Contrary to the depletion of BRE, overexpression of the protein by transfection can affect the intrinsic apoptosis by downregulating the apoptotic response to a variety of stress-related and genotoxic stimuli (Li et al., 2004) . This asymmetric sensitivity of intrinsic apoptosis to BRE levels implies that the protein is normally sequestered from the mitochondrial apoptotic system, unless it is overexpressed or the death receptors are activated. Subcellular fractionation has confirmed that BRE is not located in the mitochondria; it was found in the cytoplasmic fraction as expected, and also in the nucleus. Intriguingly, unlike t-BID, BRE is not translocated to the mitochondria during apoptotic induction (Korsmeyer et al., 2000; Li et al., 2004) . The protein is also not a member of the BCL-2 family, well known to play key roles in regulating mitochondrial apoptosis (Green and Reed, 1998; Zamzami et al., 1998; Gross et al., 1999; Cheng et al., 2001) . However, we have further shown that BRE may indeed be an in vivo prosurvival factor by demonstrating accelerated growth of the BRE-transfected Lewis lung carcinoma in mice but not in cell culture (Chan et al., 2005) . Nuclear localization of BRE has been reported by an independent group characterizing a nuclear holoenzyme complex BRCC, which contains BRCA1, BRCA2, RAD51 and BARD1, and other DNA-repair proteins. BRE and BRCC36 were found to be constituent subunits of the complex. BRE, in combination with BRCC36, was shown to enhance the E3 ubiquitin ligase activity of BARD1 and BRCA1 complex in vitro. The protein was also shown to have a protective role against ionizing irradiation-induced cell death (Dong et al., 2003) .
Taken together, the above findings indicate that BRE may be a multifunction protein, which is involved in down-modulating mitochondria-dependent death receptor-mediated apoptosis, and possibly DNA repair. Recent proteomic analysis of BRE suggests further involvement of the protein in cell cycling, protein turnover and nuclear factor-kB signaling (Tang et al., 2006) . All of the above-mentioned studies, however, relied on artificial alteration of the BRE level in cell lines through overexpression by transfection, or by siRNAmediated gene silencing. To understand the biological role of BRE, we undertook the study of the endogenous expression of the protein in normal and pathological conditions.
Results

Specificity of the anti-BRE monoclonal antibodies
Two monoclonal antibodies specific to BRE, Mab489-7 (IgG1) and Mab246 (IgG3), have been generated using human BRE protein fragment from residues 40 to 225 as immunogen. The following experiments were performed to establish the antigenic specificity of the two monoclonal antibodies. As shown in Figure 1a , western blotting by Mab489-7 and Mab246 of GSB2 (Li et al., 2004) , a stable Jurkat transfectant expressing a V5 and His-tagged BRE (GS-BRE), yielded two major protein bands, which correspond to the endogenous BRE and the transfected GS-BRE (lanes 2 and 4). These antibodies were also able to stain the 44-kDa recombinant BRE expressed in insect cell line Sf9, transduced by the recombinant baculovirus (lanes 1 and 3) . Western blotting by Mab489-7 of Sf9 transduced with fivefold serially diluted recombinant BRE baculovirus revealed the expected parallel decline in the staining intensity of the recombinant BRE band (Supplementary Figure 1a) . Mab489-7 was also used on immunoperoxidase of the transduced Sf9 cells. The results, too, confirmed the specificity of the antibody (Supplementary Figure 1b) . Immunoprecipitation of GS-BRE and the endogenous BRE from GSB2 by the monoclonal antibodies demonstrated the binding of these antibodies to the native protein ( Figure 1b) . Furthermore, co-immunoprecipitation of the endogenous BRE with GS-BRE by anti-V5 antibody (lane 6, lower panel) indicated association between the transfected BRE and the endogenous protein. Finally, BRE-specific siRNA was able to knock down the western blotting signal of the monoclonal antibodies (Figure 1c, lanes 3 and 6) . These data, taken together, establish the BRE specificity of our monoclonal antibodies.
Expression of BRE in cell lines and mouse organs Western blotting of a panel of cell lines was performed using both monoclonal antibodies Mab489-7 and Mab246, the former of which is able to yield a stronger signal than the latter in this immunodetection method. Shown here in Figure 2a are the western blotting results using Mab489-7. The 44-kDa BRE was highly expressed in all of the mammalian cell lines, but as expected not detected in Sf9. Western blotting of mouse tissues ( Figure 2b ) revealed expression of BRE in all of the tissue samples. Highest expression of the protein was found in the lungs, spleen and thymus. Lowest expression was observed in the heart and liver. Skeletal muscle showed a peculiar pattern, resulting from the interference by the presence of a large amount of unstained protein in the 44-kDa region. Same results were obtained using Mab246, which required three times longer exposure time in autoradiography (Supplementary Figure 2) . Polyclonal antibodies available from all known sources were used on western blotting of cell lines, and found nonspecific to BRE (Supplementary Figure 3) .
Significant overexpression of BRE in human hepatocellular carcinoma
Low expression of BRE in mouse livers prompted us to investigate the protein expression status in human livers by immunohistochemistry using Mab246, as the other monoclonal antibody, Mab489-7, performs poorly in this method of immunodetection. Specificity of Mab246 to BRE in immunohistochemistry is demonstrated in Supplementary Figure 4 , in which HeLa with siRNAmediated knockdown of BRE also showed reduced staining by the monoclonal antibody. As shown in Figure 3a , the histologically normal tissue of a hepatitis B virus-negative benign liver lesion displays positive nuclear staining of BRE in less than 5% of hepatocytes. Only the bile ducts and Kupffer cells are uniformly strong in nuclear staining. Study of four more resected specimens consistently revealed 0 to o5% positively stained hepatocytes. Thus, we considered 5% or less BRE-positive hepatocytes as the normal BRE expression cutoff value in livers. The general association of the overexpression of antiapoptotic proteins with tumorigenesis compelled us to look further into the BRE expression status of malignant liver specimens. A total of 123 separate cases of primary human hepatocellular carcinoma (HCC) was available as formalin-fixed paraffin-embedded archival specimens for the immunohistochemistry. BRE expression levels scored as the percentage of positively stained hepatocytes and carcinoma in the tumoral and non-tumoral regions, respectively, within the same liver resection specimen were compared, and are graphically presented in Figure 4a . Individual scores with associated clinicopathologic parameters are listed in Supplementary Table 1 . As shown in Figure 4a , the median BRE expression score of the tumoral regions was remarkably higher than that of the non-tumoral regions with the statistical significance reaching the P-value o2.2eÀ16. Furthermore, while overexpression of BRE (that is >5% cutoff value) was observed only in 13.8% of the non-tumoral regions, it was found in 74% of the tumoral regions. Figure 3b shows an example of the strong BRE expression in the tumoral region. Among the non-tumoral regions, comparison of the median scores for BRE expression between the cirrhotic (n ¼ 89) and non-cirrhotic specimens (n ¼ 23) revealed no statistical significance at P ¼ 0.182. Figure 3c shows an example of the normal, low BRE expression found in the majority of the cirrhotic non-tumoral regions (74/89). Figure 3d shows the strongest BRE-positive specimen among the remaining 15 cirrhotic non-tumoral regions that overexpressed BRE. Use of Mab489-7 on western blotting of 10 pairs of fresh HCC and adjacent non-tumoral tissue also showed upregulation of BRE in nine of the samples (Supplementary Figure 5) . The strong expression of BRE by bile ducts and Kupffer cells in both of the non-tumoral and tumoral tissues, however, rendered the western blotting a less-sensitive method than immunohistochemistry on detecting overexpression of BRE in HCC.
Kruskal-Wallis test of the BRE expression levels of HCC tumoral region specimens revealed statistical significance (P ¼ 0.049) between the three histologic grades: well, moderately and poorly differentiated, each of them comprising 25, 83 and 15 specimens, respectively. Subsequent Mann-Whitney U-test revealed significant difference between the well and moderately differentiated HCC (P ¼ 0.017). Difference between the well and poorly differentiated HCC did not reach statistical significance (P ¼ 0.09), which is evidently due to the small sample size of the latter (Figure 4b ). Taken together, these immunohistochemistry data show a strong link between overexpression of BRE with HCC.
Attenuation of Fas-induced hepatitis in liver-specific BRE transgenic mice To directly test the in vivo anti-apoptotic role of BRE, we generated liver-specific BRE transgenic mice and subjected the mice to injection of anti-Fas agonist antibody, Jo-2, for induction of acute liver failure. Expression of the transgenic BRE was controlled by a transthyretin (TTR) promoter fragment, which has been shown to drive high levels of liver-specific transgene expression (Yan et al., 1990) . To distinguish between the transgenic human BRE and the endogenous mouse counterpart, which are 99% identical, the C terminus of the transgenic protein was tagged with a V5 epitope. Tissue blotting of the transgenic mice by anti-V5 antibody showed strong expression of the transgenic protein, V5-BRE, in liver, weak expression in the ear skin and none in other tissues (Supplementary Figure  6a) . Immunohistochemical staining revealed mosaic hepatocyte expression pattern (Supplementary Figures  6b and c) characteristic of transgenes driven by this TTR promoter fragment (Rausa et al., 2000; Yu et al., 2007) . These transgenic mice showed no detectable abnormalities in liver histology and overall phenotype. As shown in Figure 5a , 65% (13/20) of the transgenic mice survived at 5 h after induction of Fas-mediated acute liver failure, whereas only 15% (3/20) of the non-transgenic littermates remained alive. The difference between the two groups was statistically significant (log-rank test P ¼ 0.0032; Mann-Whitney U-test P ¼ 0.014). Autopsies of mice that died of Jo-2 treatment confirmed severe liver damage with extensive hemorrhage and apoptosis (Figures 5b and c) . The median level of liver damage and apoptosis sustained by the surviving non-transgenic mice (14% of TdTmediated dUTP nick end labeling-positive nuclei averaged from four random fields, range ¼ 7.7-42.3%) was also more severe than that of the transgenic group (12.9%, range ¼ 0-26.4%) (Figures 5d-g ).
Regulation of BRE expression
Western blotting of the transgenic livers by Mab489-7, which stains both the transgenic human BRE and the endogenous mouse protein, revealed not only the highly expressed transgenic protein, V5-BRE, but also the diminished expression of mouse BRE (Figure 6a ).
Real-time reverse transcription-PCR, however, showed no difference in the mouse Bre transcript level between the transgenic and the non-transgenic littermates (Table 1) , indicating post-transcriptional downregulation of mouse BRE protein in the transgenic livers. Unlike the transgenic livers, no reduction of the endogenous BRE was detected in the HCC cell line, Hep3B, expressing TTR-driven V5-BRE or GS-BRE, and in the Jurkat transfectant, GSB2, expressing GS-BRE (Figure 6b , compare lanes 1-3 with 4 and 5, and Figure 2a, lanes 1 and 2) . This indicates a lack of the post-transcriptional control of the BRE level in these cell lines.
Discussion
The objective of this work is to study the biological role of BRE. We combined monoclonal antibody production, immunohistochemistry of human cancer samples and transgenic mouse generation to investigate how BRE is expressed in normal and pathological conditions, and address the in vivo effect of overexpression of the protein. Our work has demonstrated expression of BRE in all of the mammalian cell lines and mouse organs analysed. Remarkably, all the cell lines express a high level of BRE. By contrast, BRE expression varies among mouse organs, with the lungs and lymphoid organs showing the highest levels comparable to the cell lines. Livers and hearts, on the other hand, express little of the protein. Similar to the mouse counterpart, normal human livers express little BRE. HCC, however, shows highly significant elevation of the BRE level, which is more marked in the tumors of higher histologic grades. To directly address the biological consequence of BRE overexpression in the liver, we have generated liverspecific transgenic BRE mice and found that these mice were significantly less susceptible to Fas-mediated fulminant lethal liver failure than the non-transgenic littermates. Finally, we have observed diminished level of mouse endogenous BRE in livers expressing the transgenic human BRE. Overexpression of BRE by transfection in cell lines of liver and non-liver origins, by contrast, had no effect on the endogenous protein level.
Anti-Fas agonist antibody-induced lethal hepatic failure is a well-established in vivo model for the apoptosis that depends on amplification by the mitochondrial apoptotic pathway (Ogasawara et al., 1993) . Thus, mice with homozygous knockout of Bid, or transgenic overexpression of either BCL-2 or BCL-X L in the liver, showed significantly attenuated Fasmediated hepatitis (Lacronique et al., 1996; Rodriguez et al., 1996; de la Coste et al., 1999a; Yin et al., 1999) . The present demonstration of better survival of the liver-specific BRE transgenic mice compared with the non-transgenic littermates in the model is consistent with our previous findings in cell lines showing inhibition of t-BID-induced mitochondrial release of proapoptotic proteins by overexpressed BRE (Li et al., 2004) . However, we have also noted that our transgenic mice were not as well protected from the Fas-induced lethal liver failure as the BCL-2 transgenic and Bid-knockout mice. This is likely to have resulted from the diminished level of the mouse endogenous BRE in the transgenic livers. This also indicates that in the normal liver at least, a regulatory system operates to prevent building up of excessive BRE. Owing to the strong expression of the transgene, the BRE level in the transgenic livers remained considerably higher than the level of the mouse protein in the non-transgenic livers, accounting for the significant difference between the two groups in response to the anti-Fas antibody treatment.
The liver-specific BRE transgenic mouse model was generated to mimic HCC, in which there was overexpression of BRE. It is clear from our immunohistochemistry work on more than a hundred HCC samples that overexpression of BRE is significantly specific to the malignant cells, sparing in most cases the hepatocytes in the non-tumoral area, whether with cirrhosis or not. We have not observed liver cancer in our transgenic mice as old as 16 months of age, which indicates that inordinate, high expression of BRE alone is not sufficient to cause malignancy in the organ. This is in line with the current general understanding that reduced apoptosis is not a cause but an important susceptibility factor for tumorigenesis. Upregulation of antiapoptotic function allows cells to survive long enough to accumulate more transforming mutations, and to counter triggering of apoptosis commonly accompanied with oncogenic signaling (Cory et al., 2003; Lowe et al., 2004; Zhivotovsky and Orrenius, 2006) . Paradoxically, transgenic expression of the antiapoptotic BCL-2 and knockout of the proapoptotic BCL-2 family protein, BID, resulted in reduced incidence of liver cancer induced by c-MYC, transforming growth factor-a and diethylnitrosamine (de la Coste et al., 1999a; Vail et al., 2001; Bai et al., 2005) . The suppression of liver tumorigenesis has been attributed to the inhibition of liver cell proliferation caused by BCL-2 expression or deletion of BID (Pierce et al., 2002; Bai et al., 2005) . It was shown earlier in cell culture conditions that BCL-2 and its homologs including BCL-X L can inhibit cellcycle entry (O'Reilly et al., 1996) . Subsequent work demonstrated that the inhibition of cell-cycle entry is not a mandatory property of the antiapoptotic function of BCL-2, as these two activities are separable (Huang et al., 1997) . Furthermore, liver-specific transgenic expression of BCL-X L , in contrast to that of BCL-2, has been shown to result in earlier occurrence of the c-myc-induced liver cancer (de la Costes et al., 1999b) . It could be that BCL-X L may not manifest the antiproliferative activity in vivo, or the effect of antiproliferative activity is readily outweighed by that of the antiapoptotic function of the protein. Thus, reduced apoptosis may still be an independent tumorsusceptibility factor in the liver, as it has already been shown in a wide range of other tissues (Cory et al., 2003; Zhivotovsky and Orrenius, 2006) . Overexpression of BRE, Expression of antiapoptotic BRE in liver cancer BC-L Chan et al which shares no homology with BCL-2, and is therefore unlikely to have its antiproliferative function, should promote tumorigenesis. The high expression of BRE in all human and mouse cell lines analysed, regardless of their tissue origins, and in our fortuitous choice of HCC, suggests that overexpression of BRE could be a common early event in tumor development. Moreover, the strong association of BRE overexpression with HCC suggests an immediate possibility of developing BRE as a tumor marker or therapeutic target for this cancer at least.
Materials and methods
Generation of anti-BRE monoclonal antibodies
The general procedures for hybridoma generation and screening for antibody activities were performed according to standard protocol (Kohler and Milstein, 1975) . The immunogen was a polypeptide of BRE from residues 40 to 225 fused at the C terminus with a 12-mer LMP1 epitope sequence. The protein was expressed in Escherichia coli using an inducible bacterial ThioFusion expression system (Invitrogen, Carlsbad, CA, USA), and was affinity purified using an anti-LMP1 monoclonal antibody, 516-5 (Chan et al., 2002) . Details of the immunization and screening protocol are in Supplementary Materials and methods.
Generation of recombinant baculovirus
Full-length human BRE and green fluorescent protein-coding complementary DNA (cDNA) PCR fragments were cloned into pFastBacHT B baculoviral vector (Invitrogen), sequence verified and used for generation of recombinant baculovirus according to the manufacturer's protocol. A 1:200 dilution of P3 viral stock was used for infection of Sf9 for the immunoperoxidase study.
Generation of transgenic mice TTR-V5-BRE transgene was constructed by cloning the coding region for the full-length BRE with a C-terminal V5 tag into the unique StuI site of a TTR promoter fragmentcontaining liver-specific expression vector. Transgenic mice were generated by microinjection as reported previously (Ching et al., 2000) . All animals were housed in the Laboratory Animal Services Centre of the Chinese University of Hong Kong. The experimentation has been approved by the Animal Research Ethics Committee of the Chinese University of Hong Kong.
Induction of lethal hepatic apoptosis by anti-Fas agonist antibody Transgenic and non-transgenic littermates of 2-month olds were injected intraperitoneally with 10 mg of anti-Fas agonist antibody, Jo-2 (BD Biosciences, San Jose, CA, USA) in 100 ml of phosphate-buffered saline. The treatment was performed blindly of the transgenic status of the mice. Survival of the mice was monitored till the end of a 5-h period, at which point all surviving mice were terminated. Livers were collected from all of the mice, fixed in buffered formalin and embedded in paraffin. Four micrometer sections were then cut for hematoxylin and eosin staining and TdT-mediated dUTP nick end labeling assay, the latter of which was performed using the ApopTag In Situ Apoptosis Detection Kit (Millipore Corporate, Billerica, MA, USA) according to the manufacturer's manual.
Real-time reverse transcription-PCR analysis of liver cDNA of transgenic and non-transgenic mice cDNA reverse transcribed from the total RNA extracted from liver tissue was subjected to real-time PCR using AmpliTaq Gold (Applied Biosystems, Foster City, CA, USA), Sybr Green I (Invitrogen) and i-Cycler (Bio-Rad Laboratories, Hercules, CA, USA). Triplicate reactions were performed for each sample and primer sets. For amplification of the cDNA derived from the transgene, the forward and reverse primers were, respectively, 53U21 (5 0 -TTGCCTCGCTGGACTGGTATT) and 360L21 (5 0 -GGCGGCTACATTGGAATTGGT). For the endogenous mouse Bre cDNA, the forward primer was MB234U19 (5 0 -AGAGCTGCCTCCTGATTTC) and the reverse primer was MB339L19 (5 0 -CTCCTTCACCACGAGCAAC). For amplifying mouse Gapdh cDNA, the forward and reverse primers were, respectively, MG393U20 (5 0 -GTGGAGCCAAAAGGGT CATC) and MG559L20 (5 0 -TCATGAGCCCTTCCACAATG). All the primers were synthesized by Invitrogen.
Immunohistochemical staining
Paraffin-embedded sections were prepared from the tissue array blocks and were dewaxed in xylene and rehydrated in a graded series of ethanol. Microwave antigen retrieval was performed in EDTA for 21 min. Primary antibody against BRE (anti-BRE monoclonal antibody supernatant, Mab246) was applied and incubated at 1:128 dilution for 32 min at 371C. Color development was performed using the universal horseradish peroxidase Multimer ultraview detection kit (Ventana Medical System, Victoria, Australia) and the NexES IHC system (Ventana Medical System). Mayer hematoxylin was used for counterstaining.
Statistical analysis
Statistical analysis was performed using R software (version 2.4.0). Wilcoxon signed-rank and sum-rank tests were used for paired and unpaired data analyses, respectively; KruskalWallis test for multiple groups; and Mann-Whitney U-test for comparing pairs of groups following detection of significance by Kruskal-Wallis test. Kaplan-Meier plot and log-rank test were used in mouse survival analysis. P-values o0.05 were considered statistically significant.
